Some Irbesartan tablets are being recalled due to the presence of an impurity that is a probable human carcinogen.
Certain lots of a blood pressure medication have been recalled because they may contain an impurity believed to cause cancer, the U.S. Food and Drug Administration announced Tuesday.
Some Irbesartan tablets manufactured by ScieGen Pharmaceuticals and labeled as Westminster Pharmaceuticals and Golden State Medical Supply, Inc (GSMS) are impacted by the voluntary recall.
The FDA says the impacted products are being recalled due to the presence of an impurity: N-nitrosodiethylamine (NDEA). The International Agency for Research on Cancer lists the substance as a probable human carcinogen, according to the FDA.
The FDA has published a complete list of effected drug lots, which were sold in 75 mg, 150 mg, and 300 mg doses.
For patients who find their medication is among the recalled batches, the FDA recommends contacting a pharmacist or physician about alternate treatment. Patients should continue taking their medication until an alternative treatment can be arranged, as immediate discontinuation could be more harmful, the FDA says.
|Read on: FDA: Blood pressure drug Irbesartan recalled for possible cancer risk|